Puma Biotechnology Inc
PBYI3.190USD
+0.120+3.91%
交易中 （美东）报价延迟15分钟
158.27M总市值
4.16市盈率 TTM
关于 Puma Biotechnology Inc 公司
Puma Biotechnology, Inc. 是一家生物制药公司。该公司专注于开发和商业化产品以增强癌症治疗。该公司的主要产品是 NERLYNX，一种口服的 neratinib，用于治疗 HER2 阳性乳腺癌。Neratinib 是一种强效的不可逆酪氨酸激酶抑制剂 (TKI)，可阻断通过表皮生长因子受体 HER1、HER2 和 HER4 的信号转导。该公司还参与了 alisertib 的开发和商业化。 Alisertib 是一种选择性小分子极光激酶 A 抑制剂，旨在破坏有丝分裂，导致依赖极光激酶 A 的快速增殖肿瘤细胞凋亡。其来那替尼在治疗其他几种癌症方面也有临床应用，包括 HER2 或表皮生长因子受体 (EGFR) 过度表达或突变的其他肿瘤类型，例如乳腺癌、宫颈癌、肺癌或其他实体瘤。
公司简介
公司代码PBYI
公司名称Puma Biotechnology Inc
上市日期Mar 21, 2012
CEOMr. Alan H. Auerbach
员工数量172
证券类型Ordinary Share
年结日Mar 21
公司地址10880 Wilshire Blvd.
城市LOS ANGELES
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编90024
电话14242486500
网址https://www.pumabiotechnology.com/
公司代码PBYI
上市日期Mar 21, 2012
CEOMr. Alan H. Auerbach
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Alan H. Auerbach
Mr. Alan H. Auerbach
Chairman of the Board, President, Chief Executive Officer, Secretary
Chairman of the Board, President, Chief Executive Officer, Secretary
6.90M
-0.68%
Mr. Brian M. Stuglik
Mr. Brian M. Stuglik
Independent Director
Independent Director
94.96K
+24.85%
Ms. Allison Dorval, CPA
Ms. Allison Dorval, CPA
Independent Director
Independent Director
75.39K
+25.65%
Mr. Jay M. Moyes, CPA
Mr. Jay M. Moyes, CPA
Lead Independent Director
Lead Independent Director
53.32K
+10.35%
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
41.85K
-39.22%
Dr. Adrian M. Senderowicz, M.D.
Dr. Adrian M. Senderowicz, M.D.
Independent Director
Independent Director
27.00K
--
Dr. Troy E. Wilson, J.D., Ph.D.
Dr. Troy E. Wilson, J.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Hunt
Mr. Douglas Hunt
Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law Officer
Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law Officer
--
--
Mr. Michael P. (Mike) Miller
Mr. Michael P. (Mike) Miller
Independent Director
Independent Director
--
--
Mr. Mariann Ohanesian
Mr. Mariann Ohanesian
Investor Relations
Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Alan H. Auerbach
Mr. Alan H. Auerbach
Chairman of the Board, President, Chief Executive Officer, Secretary
Chairman of the Board, President, Chief Executive Officer, Secretary
6.90M
-0.68%
Mr. Brian M. Stuglik
Mr. Brian M. Stuglik
Independent Director
Independent Director
94.96K
+24.85%
Ms. Allison Dorval, CPA
Ms. Allison Dorval, CPA
Independent Director
Independent Director
75.39K
+25.65%
Mr. Jay M. Moyes, CPA
Mr. Jay M. Moyes, CPA
Lead Independent Director
Lead Independent Director
53.32K
+10.35%
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
41.85K
-39.22%
Dr. Adrian M. Senderowicz, M.D.
Dr. Adrian M. Senderowicz, M.D.
Independent Director
Independent Director
27.00K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月1日 周二
更新时间: 7月1日 周二
持股股东
股东类型
持股股东
持股股东
占比
Auerbach (Alan H)
13.90%
Acorn Capital Advisors, LLC
7.94%
The Vanguard Group, Inc.
7.39%
BlackRock Institutional Trust Company, N.A.
6.05%
Acadian Asset Management LLC
4.05%
Other
60.67%
持股股东
持股股东
占比
Auerbach (Alan H)
13.90%
Acorn Capital Advisors, LLC
7.94%
The Vanguard Group, Inc.
7.39%
BlackRock Institutional Trust Company, N.A.
6.05%
Acadian Asset Management LLC
4.05%
Other
60.67%
股东类型
持股股东
占比
Investment Advisor
32.15%
Investment Advisor/Hedge Fund
22.16%
Individual Investor
15.50%
Hedge Fund
9.95%
Research Firm
1.20%
Pension Fund
0.39%
Venture Capital
0.25%
Bank and Trust
0.09%
Insurance Company
0.03%
Other
18.26%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
252
40.67M
81.93%
-7.05M
2025Q1
256
39.74M
80.10%
-6.90M
2024Q4
254
38.30M
77.36%
-8.34M
2024Q3
246
40.62M
82.78%
-5.24M
2024Q2
238
41.70M
86.51%
-237.42K
2024Q1
243
40.11M
83.30%
-422.18K
2023Q4
241
36.65M
77.08%
-4.19M
2023Q3
280
35.58M
74.91%
-9.53M
2023Q2
294
33.81M
72.39%
-18.15M
2023Q1
308
36.08M
77.40%
-14.44M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Auerbach (Alan H)
6.95M
13.99%
-21.51K
-0.31%
Apr 21, 2025
Acorn Capital Advisors, LLC
3.94M
7.94%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
3.67M
7.39%
+25.84K
+0.71%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.00M
6.05%
-48.98K
-1.60%
Mar 31, 2025
Acadian Asset Management LLC
2.01M
4.05%
+36.02K
+1.83%
Mar 31, 2025
Renaissance Technologies LLC
1.83M
3.69%
+73.70K
+4.20%
Mar 31, 2025
Millennium Management LLC
1.39M
2.79%
-508.93K
-26.87%
Mar 31, 2025
Athyrium Capital Management, LP
1.26M
2.53%
--
--
Sep 30, 2024
American Century Investment Management, Inc.
1.15M
2.32%
+201.28K
+21.22%
Mar 31, 2025
Geode Capital Management, L.L.C.
955.46K
1.92%
+36.02K
+3.92%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Janus Henderson Small Cap Growth Alpha ETF
0.67%
Royce Quant Small-Cap Quality Value ETF
0.25%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.23%
Lattice Hartford Multifactor Small Cap ETF
0.11%
WisdomTree US SmallCap Fund
0.04%
iShares Micro-Cap ETF
0.03%
Franklin US Small Cap Multifactor Index ETF
0.02%
Fidelity Enhanced Small Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
查看更多
Janus Henderson Small Cap Growth Alpha ETF
占比0.67%
Royce Quant Small-Cap Quality Value ETF
占比0.25%
Janus Henderson Small/Mid Cap Growth Alpha ETF
占比0.23%
Lattice Hartford Multifactor Small Cap ETF
占比0.11%
WisdomTree US SmallCap Fund
占比0.04%
iShares Micro-Cap ETF
占比0.03%
Franklin US Small Cap Multifactor Index ETF
占比0.02%
Fidelity Enhanced Small Cap ETF
占比0.02%
Avantis US Small Cap Equity ETF
占比0.02%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
